Healthspan Is the Next Big Bet for Illinois Life Sciences

Healthspan Is the Next Big Bet for Illinois Life Sciences

by John Conrad | Jun 8, 2026 | Member News

A City Club of Chicago panel put longevity science on the civic agenda - and Illinois is already positioning to lead.

A few years ago, longevity science lived mostly in academic journals and Silicon Valley pitch decks. Today, it's a topic serious enough to draw some of Chicago's top physicians, economists, and policymakers to a midday City Club panel - and substantive enough to fill the room.

The conversation, framed around healthspan and the future of longevity, featured four panelists with complementary vantage points: Dr. Douglas Vaughan, director of Northwestern's Potocsnak Longevity Institute; Dr. Francesca Duncan, a pioneering reproductive biologist at Northwestern Feinberg School of Medicine; Dr. Jay Bhatt, managing director of the Deloitte Center for Health Solutions; and Christy George, President and CEO of the Illinois Economic Development Corporation. Moderating was City Club Chair Dan Gibbons.

What emerged was both a scientific primer and an economic argument - and a compelling case that Illinois is uniquely positioned to lead what may be the defining health frontier of the next generation.

First, a Definition

The panel started by drawing a critical distinction that underlies everything else in this conversation: lifespan versus healthspan.

Lifespan is the number of years you live. Healthspan is the number of years you live well - free from chronic disease, cognitive decline, and functional limitation. Right now, there is roughly a 10-year gap between the two for the average American. The goal of longevity science isn't simply to add years to life; it's to compress the period of morbidity at the end of it.

Dr. Vaughan added another layer to the framework: the difference between chronological and biological age. Your chronological age is "cosmically indifferent," as he put it - you can't negotiate with your birthday. But biological age is malleable. It reflects how your genes, exposures, and behaviors have actually affected your body's systems over time. Crucially, we now have tools to measure it with real precision - and growing evidence that we can do something about it.

The Science Is Moving Fast

Northwestern's Human Longevity Laboratory offers a window into where clinical longevity science is heading. In about 2.5 hours, participants move through a series of stations that produce a comprehensive biological age profile - physiological and functional measures, deep molecular profiling, and AI-powered assessments that would have seemed like science fiction a decade ago.

One example: participants look into a camera for a retinal scan. Within seconds, an AI system trained on hundreds of thousands of images returns an estimated biological age and flags risk signals for conditions like kidney disease. Another: a standard 12-lead EKG - a tool cardiologists have used for decades - can now be analyzed by machine learning to estimate a patient's age, sex, and seven-year cardiovascular mortality risk.

"Those are tools that cost pennies to operate," Vaughan noted. "It makes it scalable, affordable, and available to everybody."

Dr. Duncan's work adds a dimension that has been underrepresented in longevity research: the distinct aging trajectory of women. The ovary, she argued, is not merely a fertility organ - it is a critical driver of long-term health outcomes across cardiovascular, skeletal, cognitive, metabolic, and immune systems. Ovarian aging begins in women's mid-thirties, and its effects cascade across decades.

The result is what researchers call the "mortality paradox": women live longer than men on average, but actually spend more time in poor health and frailty. Understanding - and ultimately intervening in - ovarian aging trajectories is, Duncan argued, essential to achieving true health equity between the sexes.

The Economic Case Is Stark

The science alone could make the case. But Christy George made the economic argument impossible to ignore.

Chronic disease costs the United States between $3 and $4 trillion annually - roughly 20 percent of GDP. For Illinois, that translates to approximately $142 billion, with $85 billion in direct medical treatment costs and $34 billion in lost workplace productivity. And those numbers are heading in the wrong direction: projections suggest total U.S. chronic disease costs could reach $47 trillion over the next 15 years.

Against that backdrop, Deloitte's research offers a striking counter-scenario. Dr. Bhatt cited findings suggesting that a serious national commitment to healthspan extension could save Medicare $500 billion by 2040 and reduce system-wide costs by $2.2 trillion. The math on prevention isn't complicated - it's just politically and organizationally hard to execute at scale.

George also surfaced the geographic equity dimension. Life expectancy in the Loop: 82-83 years. Life expectancy in West Garfield Park: approximately 66. A 20-year gap within a single city. Similar disparities show up between high-income suburbs and rural downstate communities. Longevity science that doesn't address the social and environmental drivers of accelerated aging won't close those gaps.

Illinois Is Positioned to Lead - But Has to Own It

Perhaps the most energizing part of the panel was the discussion of Illinois's competitive position in this space.

The state already has the ingredients: world-class research universities (Northwestern, University of Chicago, UIC, University of Illinois), a deep life sciences industry ecosystem, a collaborative culture that produced the Chan Zuckerberg Biohub Illinois partnership, and continued major capital investment. George cited AbbVie's $600 million manufacturing expansion in North Chicago and Pfizer's $1.5 billion facility investment as signals that life sciences companies are doubling down on Illinois - and that they're doing so because of the innovation ecosystem, not in spite of it.

Dr. Vaughan announced that the Human Longevity Laboratory is actively building a network of partner sites, with UIC already established as a collaborator. The ambition is to replicate the lab model across Illinois and eventually nationally - creating a distributed research and clinical infrastructure that can reach populations who would never walk into a Northwestern clinic on their own.

Dr. Bhatt's framing of the equity imperative was pointed: "We are really interested in the 99 percent of people in the world that need our help, particularly people that are disadvantaged for some reason." Longevity science designed for tech executives will not fix West Garfield Park. AI tools embedded in community health clinics might.

What Comes Next

The panel closed with a call to action directed at everyone in the room - and by extension, the broader civic community.

Talk about it. Share the research. Engage with the Illinois Multi-Sector Plan for Aging (Engage Illinois). Advocate for the policy infrastructure - including regulatory pathways for longevity-focused therapeutics - that doesn't yet exist. Connect the science to the equity work. And recognize that this is not a single institution's project. The scale of the opportunity - and the urgency of the challenge - requires the full Illinois ecosystem pulling in the same direction.

The biology of aging has been "remarkably demystified," in Vaughan's words. The tools to measure and influence it are here. The industry investment is flowing. The only question is whether Illinois will organize itself to lead - or watch the opportunity migrate somewhere else.